Prospective Partners

PDS welcomes additional partners to develop the novel Versamune®-based immunotherapies, as well as human and veterinary preventive vaccines.

Parties interested in collaborating with PDS or in licensing the Versamune® vector technology for use in vaccines and at: immunotherapies should contact PDS Biotechnology Corporation.

Michael King

Email: mking@pdsbiotech.com
Tel: 609-610-4604

For Scientific Inquiries, please contact:

Dr. Greg Conn

Email: gconn@pdsbiotech.com
Tel: 732-640-0045

  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway one
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144